Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)
Dunhua, CN
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.41% | -2.16% | -7.61% | -9.35% | -9.69% | -11.67% | +5.57% | +1.23% | +9.87% | -7.31% | +1,005.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-10.6% Q1'26: -17.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+60.6% ★ Q1'26: +67.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2.4% Q1'26: -3.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-7.1% Q1'26: +7.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.5% Q1'26: +0.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-4.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×85.08× ★ Q1'26: 6.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
3.45B
est: 3.46B (-0.2%)
|
2.61B
est: 4.12B (-36.6%)
|
2.34B
est: 4.90B (-52.4%)
|
| EBITDA |
339.83M
est: 258.77M (+31.3%)
|
45.48M
est: 270.16M (-83.2%)
|
25.92M
est: 321.50M (-91.9%)
|
| EBIT |
134.53M
est: -2.62M (+5,227.8%)
|
-160.40M
est: -37.34M (-329.5%)
|
-165.14M
est: -44.44M (-271.6%)
|
| Net Income |
1.46B
est: 1.94B (-24.8%)
|
1.55B
est: 2.14B (-27.6%)
|
2.40B
est: 2.46B (-2.5%)
|
| SGA |
1.35B
est: 1.56B (-13.0%)
|
1.06B
est: 1.77B (-40.4%)
|
1.09B
est: 2.11B (-48.5%)
|
| EPS |
1.30
est: 1.65 (-21.2%)
|
1.32
est: 1.90 (-30.5%)
|
2.12
est: 2.18 (-2.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-25 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.17% | 60.6K | 0.65% |
| 2 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.05% | 8.5K | 0.65% |
| 3 | Franklin FTSE China ETF FLCH | 0.01% | 34.4K | 0.19% |
| 4 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 150.0K | 0.19% |
| 5 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 72.2K | 0.24% |
| 6 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 72.2K | 0.24% |
| 7 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 11.6K | 0.58% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 178.2K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 178.2K | 0.17% |
| 10 | Vanguard FTSE All-World UCITS ETF (USD) Accumulating VWRA.L | 0.00% | 2.07M | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao Wang | Deputy General Manager | — | male |
| Kai Yang | Deputy GM & Director | — | male |
| Qiang Li | Accounting Supervisor | — | — |
| Shuqin Guo | Vice Chairman & GM | — | female |
| Shuyuan Zhang | Chief Financial Officer, Financial Director, Deputy GM & Director | — | female |
| Xiaolin Lin | Deputy General Manager | — | male |
| Zhen Yu Wang | Deputy GM, Secretary of the Board & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000623.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
